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Calcium signalingo peripheral nerve culminates in development of peripheral diabetic neuropathy
(PDN), one of the most devastating complications of diabetes mellitus and a leading cause of foot amputation.
The pathogenesis of PDN occurs as a consequence of complex interactions among multiple hyperglycemia-
initiated mechanisms, impaired insulin signaling, inﬂammation, hypertension, and disturbances of fatty acid
and lipid metabolism. This review describes experimental new ﬁndings in animal and cell culture models as
well as clinical data suggesting the importance of 1) previously established hyperglycemia-initiated
mechanisms such as increased aldose reductase activity, non-enzymatic glycation/glycooxidation, activation
of protein kinase C, 2) oxidative–nitrosative stress and poly(ADP-ribose) polymerase activation; 3) mitogen-
activated protein kinase and cyclooxygenase-2 activation, impaired Ca++ homeostasis and signaling, and
several other mechanisms, in PDN.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Diabetic distal symmetric sensorimotor polyneuropathy affects at
least 50%of diabetic patients, and is the leading causeof foot amputation
[1]. Two largest clinical trials in subjectswith Type 1 and Type 2 diabetes
i.e., Diabetes Control and Complication Trial (DCCT) and UK Prospective
Diabetes Study (UKPDS), indicate that intensive therapy and improved
blood glucose control reduce incidence and slow progression of
peripheral diabetic neuropathy (PDN) thus implicating hyperglycemia
as a leading causative factor [1–3]. A number of mechanisms have been
proposed to link chronic hyperglycemia to diabetes-induced deﬁcits in
motor and sensory nerve conduction velocities (MNCV and SNCV) and
smallﬁber sensoryneuropathy. Thevascular concept of PDN implies that
diabetes-induced endothelial dysfunction with resulting decrease in
nerve bloodﬂow(NBF), vascular reactivity, and endoneurial hypoxiahas
a key role in functional andmorphological changes in the diabetic nerve
[4]. Endothelial changes in vasa nervorum have been attributed to
multiple mechanisms including increased aldose reductase (AR)
activity, non-enzymatic glycation and glycoxidation, activation of
protein kinase C, oxidative–nitrosative stress, changes in arachidonicitted from the special issue on
5, Pages 393–496 (May 2009),
ll rights reserved.acid and prostaglandin metabolism [4], and, recently, decreased
expression of the vanilloid receptor 1 in vasa nervorum [5], increased
production of angiotensin (AT) II and activation of the AT1-receptor [6],
activation of poly(ADP-ribose) polymerase-1 (PARP) [7], nuclear factor-
κB (NF-κB, [8]), cyclooxygenase-2 (COX-2) [9], and others. The
neurochemical concept of PDN suggests the importance of similar
mechanisms in the neural elements of PNS i.e., Schwann cells, spinal
cord oligodendrocytes, and dorsal root ganglion neurons. Other pa-
thobiochemical mechanisms such as 1) metabolic abnormalities i.e.,
downregulation of Na+/K+ATP-ase activity [10], “pseudohypoxia” — an
increase in free cytosolic NADH/NAD+ ratio putitatively linked to
increased conversion of sorbitol to fructose by sorbitol dehydrogenase
[11], changes in fatty acid and phospholipid metabolism [12], 2)
impairedneurotrophic support [13,14], 3) changes in signal transduction
[15], and 4) dorsal root ganglion (DRG) and Schwann cell mitochondrial
dysfunction and premature apoptosis [16,17], have also been invoked.
The present reviewof the recentﬁndings has twomajor objectives i.e.1)
to evaluate new experimental evidence that supports or disproves
previously formulated concepts of the pathogenesis of PDN, and 2) to
characterize newly discovered mechanisms.
2. Role for aldose reductase
The sorbitol pathway of glucose metabolism consists of two
reactions. First, glucose is reduced to its sugar alcohol sorbitol by
NADPH-dependent AR. Then, sorbitol is oxidized to fructose by NAD-
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the peripheral nerve is well documented in STZ-diabetic rodents
[18,19] and has recently been described in leptin-deﬁcient (ob/ob)
mice [20]. Interestingly and excitingly, increased sorbitol pathway
activity manifest by sciatic nerve sorbitol and fructose accumulation is
also clearly manifest in the high fat diet (HFD) model of prediabetic
neuropathy characterized by impaired glucose tolerance, increased
serumnonesteriﬁed fatty acid concentrations and insulin resistance, in
the absence of overt hyperglycemia [21]. These ﬁndings indicating that
factors, other than increased intracellular glucose concentrations, may
predispose to increased sorbitol pathway activity, support and
complement previous observations in models of non-diabetic condi-
tions i.e., myocardial ischemia [22,23] and aging [24,25]. Studies of the
effects of HFD on sorbitol pathway enzyme gene and protein
expressionmay help to identify an importantmechanism contributing
to neuropathy and cardiovascular disease in overweight and obese
individuals.
Negative consequences of the sorbitol pathwayhyperactivity under
diabetic conditions include intracellular sorbitol accumulation and
resulting osmotic stress, and generation of fructose, a 10-times more
potent glycation agent than glucose as well as fructose 1-phosphate
[26]. One group reported that increased ﬂux through SDH leads to so
called “pseudohypoxia” i.e. an increased free cytosolic NADH/NAD+
ratio [11] whereas others [27] did not ﬁnd a relation between cytosolic
or mitochondrial NAD+/NADH redox state and SDH activity in the
peripheral nerve. Two groups obtained the results indicating that
increased AR, but not SDH, activity contributes to PDN [28, 29].
The role for AR in PDN has been reviewed in detail [30]. New
evidence for the key role of AR in functional, metabolic, and
morphological manifestations of PDN has been generated in both
experimental studies in animal and cell culturemodels of diabetes and
clinical trials of AR inhibitors (ARIs). Our group demonstrated that
metabolic abnormalities of early PDN, such as mitochondrial and
cytosolic NAD+/NADH redox imbalances and energy deﬁciency, can
be reversed with an adequate dose of ARI i.e., the dose that completely
suppressed diabetes-associated sorbitol pathway hyperactivity [31].
Of particular interest are the results implicating increased AR activity
in high glucose- and diabetes-induced oxidative–nitrosative stress
[31-35] and downstream events such as activations of mitogen-
activated protein kinase (MAPK) [36,37], PARP [35], COX-2 [38], and
NF-κB [39]. AR inhibitors have been reported to counteract diabetes-
induced loss of two major non-enzymatic antioxidants, GSH and
ascorbate, lipid peroxidation, as well as nitrotyrosine formation in
peripheral nerve [20,21,35], spinal cord [20], DRG [20] and epineurial
arterioles [35] and superoxide production in vasa nervorum [35]. Our
group has also demonstrated the key role for AR in diabetes-
associated PARP activation in peripheral nerve, spinal cord, DRG, and
high glucose-exposed human Schwann cells (HSC) [20,21,35]. AR
plays a key role in diabetes-related MAPK activation in DRG neurons
[13,37]. Both PARP activation and MAPK activation are involved in
transcriptional regulation of gene expression, via the transcription
factors NF-κB, activator protein-1, p53, and others [40,41]. Activation
of these transcription factors leads to upregulation of inducible nitric
oxide synthase, cyclooxygenase-2, endothelin-1, cell adhesion mole-
cules and inﬂammatory genes [40,42]. Thus, the demonstration of a
major contribution of AR to oxidative–nitrosative stress and PARP and
MAPK activation in tissue-sites for diabetic complications allows to
predict that in the near future the link between increased AR activity
and altered transcriptional regulation and gene expression will be
established. Any product of genes controlled via PARP- and MAPK-
dependent transcription factors, regardless of how unrelated to the
sorbitol pathway this product looks from a biochemical point of view,
will be affected by a diabetes-associated increase in AR activity, and
amenable to control by AR inhibition. In accordancewith this premise,
the most recent ﬁndings have shown that increased AR activity leads
to activation of NF-κB and activator protein-1 [39], and is responsiblefor diabetes-induced COX-2 upregulation in the spinal cord oligoden-
drocytes [38] and 12/15-lipoxygenase overexpression in sciatic nerve
[21].
The role for AR in the pathogenesis of PDN is supported by ﬁndings
obtained in AR-overexpressing and AR-knockout mice. Induction of
STZ-diabetes in the mice transgenic for human AR resulted in a more
severe peripheral nerve sorbitol and fructose accumulation, MNCV
deﬁcit, and nerve ﬁber atrophy than in their non-transgenic
littermates [19]. Treatment of diabetic transgenic mice with the AR
inhibitor (ARI) WAY121–509 signiﬁcantly prevented sorbitol accu-
mulation, MNCV slowing, and the increased myelinated ﬁber atrophy
in diabetic AR-overexpressing mice [19]. Similar ﬁndings have been
obtained in another transgenic mouse model that overexpressed AR
speciﬁcally in the Schwann cells of peripheral nerve under the control
of the rat myelin protein zero (Po) promoter [43]. The transgenic mice
exhibited a signiﬁcantly greater reduction in MNCV under both
diabetic and galactosemic conditions than the non-transgenic mice
with normal AR content. In contrast, AR-deﬁcient mice appeared
protected from motor nerve conduction slowing, axonal atrophy, and
several metabolic manifestations of PDN [44]. These data lend further
support to the important role of AR in functional, metabolic and
morphological abnormalities characteristic for PDN.
The ﬁndings in transgenic and knockout mouse models are in line
with new studies with structurally diverse ARIs. Coppey et al. [45]
implicated AR in diabetes-induced impairment of vascular reactivity
of epineurial vessels, an early manifestation of PDN, which precedes
motor nerve conduction slowing. An ARI treatment prevented the
development of thermal hyperalgesia, an event associated with early
PDN, in STZ-diabetic rats [46]. Furthermore, structurally different
ARIs, at least, partially prevented thermal hypoalgesia in rats with
more prolonged STZ-diabetes [46], as well HFD-fed [21] and ob/ob
[20] mice. Tactile allodynia was not prevented by an ARI treatment in
either STZ-diabetic rats [46] or ob/ob mice [20], although tactile
withdrawal thresholds in response to light touch with ﬂexible von
Frey ﬁlaments tended to be higher in ob/obmice treated with the ARI
ﬁdarestat compared with the corresponding untreated group. New
evidence supports the role of AR in the pathogenesis of advanced PDN.
A 15-month AR inhibitionwith ﬁdarestat dose-dependently corrected
slowed F-wave, MNCV, and SNCV in STZ-diabetic rats [47]. In the same
study, diabetes-induced paranodal demyelination and axonal degen-
erationwere reduced to the normal with such low dose of ﬁdarestat as
2 mg/kg. Other manifestations of advanced PDN such as axonal
atrophy, distorted axon circularity, and reduction of myelin sheath
thickness were also inhibited. In our study in ob/ob mice that display
clearly manifest intraepidermal nerve ﬁber loss, a sign of small
sensory nerve ﬁber degeneration, ﬁdarestat treatment partially
prevented diabetes-associated decrease in intraepidermal nerve
ﬁber density [20]. The results of several recent clinical trials of ARIs
are also encouraging and support applicability of the AR concept to the
pathogenesis of human PDN. In particular, a clinical trial with the ARI
zenarestat indicates that robust inhibition of AR in diabetic human
nerve improves nerve physiology and ﬁber density [48]. Two double-
blind placebo-controlled clinical trials of ﬁdarestat in patients with
Type 1 and Type 2 diabetes also provided a proof of efﬁcacy of ARIs
([49], and Arezzo et al., unpublished). In these trials, ﬁdarestat
improved electrophysiological measures of median and tibial MNCV,
F-wave minimum latency, F-wave conduction velocity and median
SNCV (forearm and distal), as well as subjective symptoms of PDN
such as numbness, spontaneous pain, sensation of rigidity, paresthesia
in the sole uponwalking, heaviness in the foot and hypesthesia. These
ﬁndings are consistent with the results of the most recent open-label,
prospective study conducted at 12 hospitals in the central area of
Honshu, Japan [50]. Treatment of 22 patients with ﬁdarestat
signiﬁcantly increased vibration perception threshold in the upper
and lower limbs. The symptoms such as severity of numbness in the
lower limbs, heaviness in the foot, coldness and hot ﬂushes in the
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walking on sand, sensation as if walking on an uneven road,
spontaneous pain in the lower limbs, and dizziness, were also
improved. Recently, improvement of motor and sensory nerve
conduction velocity in patients with diabetic sensorimotor poly-
neuropathy was also found with the new ARI AS-3201 (ranirestat,
[51]). The role for AR in human diabetic neuropathy is also supported
by the genetic polymorphism data [30,52].
3. Role for non-enzymatic glycation/glycoxidation
Glycation is the nonenzymatic reaction of glucose, α-oxoalde-
hydes, and other saccharide derivatives with proteins, nucleotides,
and lipids, with formation of early glycation adducts (fructosamines)
and advanced glycation end-products (AGE). Formation of some AGE
i.e., pentosidine and Nɛ-[carboxymethyl]-lysine, combines both
glycation and oxidative steps in a process termed “glycoxidation”. In
the last several years, the role for glycation/glycoxidation in diabetic
complications including diabetic neuropathy has extensively been
reviewed [53–55]. A number of new studies in animal models of
diabetes and human subjects support the role of this mechanism.
Using the state-of-the art technique i.e., liquid chromatography
with tandem MS detection, Karachalias et al. [56] produced evidence
of accumulation of fructosyl-lysine and AGE in peripheral nerve of
STZ-diabetic rats. In particular, sciatic nerve concentrations of Nɛ-
[carboxymethyl]-lysine and Nɛ-[carboxyethyl]-lysine were markedly
increased in diabetic rats compared with controls. Hydroimidazolone
AGEs derived from glyoxal, methylglyoxal and deoxyglucosone were
major AGEs quantitatively. The receptor for AGE (RAGE) was localized
both in endothelial and Schwann cells of the peripheral nerve [57].
Recently generated RAGE−/−mice appeared partially protected from
diabetes-associated pain perception loss, an indicator of longstanding
diabetic neuropathy [58]. Furthermore, in the same study, loss of pain
perception was reversed in the diabetic wild-type mice treated with
soluble RAGE. Further studies [59] revealed a dramatic and cumulative
rise in RAGE mRNA and protein expression in peripheral epidermal
axons, sural axons, Schwann cells, and sensory neurons within dorsal
root ganglia, correlating with progressive electrophysiological and
structural abnormalities in STZ-diabetic mice. In the same study,
functional and structural abnormalities of PDN, and activation of NF-
κB and PKC beta II signaling pathways were attenuated in diabetic
RAGE−/− mice. The ﬁndings in RAGE−/− mice are in line with
new “anti-glycation” agent studies that also support a pivotal role of
the AGE/RAGE axis in the pathogenesis of PDN. The new inhibitor of
AGE and advanced lipoxidation end-product (ALE) formation,
pyridoxamine, previously reported to be effective against diabetic
nephropathy and retinopathy, was found to reverse established sciatic
endoneurial NBF, MNCV and SNCV deﬁcits in STZ-diabetic rats with 8-
week duration of diabetes [60]. Of interest, this correction was
achieved in the absence of any signiﬁcant effect of the agent on the
levels of AGE/ALE, N-(carboxymethyl)lysine and n-(carboxyethyl)
lysine in total sciatic nerve protein which suggests that short-term
diabetes and pyridoxamine treatment target AGE/ALE in vasa
nervorum rather than neural components of the peripheral nerve.
Another new anti-glycation agent OPB-9195 reduced sciatic nerve
immunoreactive AGE expression, and prevented tibial motor nerve
conduction slowing, downregulation of Na+,K+-ATPase activity, and
accumulation of 8-hydroxy-2′-deoxyguanosine (a marker of DNA
oxidative damage) in STZ-diabetic rats with 24-week duration of
diabetes [61]. High-dose therapy of thiamine and benfotiamine
suppressed AGE accumulation in the peripheral nerve [62] and
reversed diabetic neuropathy [63], potentially by reducing the levels
of triose phosphates via activation of transketolase. Several in vitro
studies describe adverse effects of AGE precursors and AGE per se in
Schwann cells and DRG neurons [64–66]. In particular, methylglyoxal
was found to induce rat Schwann cell apoptosis via oxidative stress-mediated activation of p38 MAPK [64]. AGE derived from glyceralde-
hydes and glycolaldehyde, but not from glucose, induced rat Schwann
cell apoptosis, decreased cell viability and replication, decreased
mitochondrial membrane potential, activated NF-κB, and enhanced
production of inﬂammatory cytokines i.e. TNF-α and IL-β [65]. The
DRG neuron exposure to RAGE ligand S100 was associated with
increased phosphatidylinositol-3 kinase activity and enhancement of
oxidative stress, and RAGE ligand-induced changes were prevented by
the potent antioxidant alpha-lipoic acid [66].
Several new studies support the presence of AGE accumulation in
patients with diabetes mellitus. The AGE pyrraline immunoreactivity
was more intense in the optic nerve head of diabetic subjects
compared with non-diabetic controls [67]. Pronounced AGE immu-
noreactivity was detected in axons and myelin sheaths in 90% of
patients with Type 2 diabetes but not in control subjects, and the
intensity of axonal AGE positivity signiﬁcantly correlated with the
severity of morphological alterations characteristic for PDN [68]. In
the same study, AGE positivity was clearly present in endoneurium,
perineurium and microvessels of diabetic patients. Bierhaus et al. [58]
have demonstrated that ligands of RAGE, the receptor itself, activated
NF-κBp65, and IL-6 colocalized in the microvasculature of sural nerve
biopsies obtained from human subjects with diabetic neuropathy.
Furthermore, Nɛ-[carboxymethyl]-lysine, RAGE and NF-κB were found
in the sural nerve perineurium, epineurial vessels and endoneurial
vessels of subjects with impaired glucose tolerance-related poly-
neuropathy [69]. Several clinical studies support the role of glycation
in the pathogenesis of PDN and other diabetes complications
[70,71,72). In particular, it has been reported that increased accumula-
tion of skin AGE precedes and correlates with clinical manifestations
of diabetic neuropathy [70]. In another study, AGE accumulation in
skin, serum, and saliva increased with progression of neuropathy,
nephropathy and retinopathy [71]. Furthermore, serum Nɛ-[carbox-
ymethyl]-lysine concentrations were found signiﬁcantly higher in
children and adolescents with Type 1 diabetes and diabetes
complications (background retinopathy, microalbuminuria and neu-
ropathy) compared with the uncomplicated group [72].
4. Role for protein kinase C activation
PKC comprises a superfamily of isoenzymes, many of which are
activated by 1,2-diacylglycerol (DAG) in the presence of phosphati-
dylserine. PKC isoforms phosphorylate a wide variety of intracellular
target proteins and have multiple functions in signal transduction-
mediated cellular regulation. The role for PKC in the pathogenesis of
PDN has been reviewed in detail [73]. PKC is activated in vasa
nervorum of diabetic rats [74], and vessel-rich epineurial vessels of
diabetic mice [75]. PKC has been reported decreased [76], unchanged
[74] or increased [77] in the diabetic rat nerve, and decreased in
endoneurial tissue of diabetic mouse nerve [75]. PKC activity was
markedly reduced in DRG neurons of the wild-type STZ-diabetic mice
and further reduced in the diabetic mice overexpressing human AR
[78]. These changes were associated with reduced expression and
activity of the membrane PKC-α isoform that translocated to cytosol.
The membrane PKC-IIβ isoform expression was increased in AR-
overexpressing diabetic transgenic mice, but not in thewild-typemice
[78].
The experimental evidence obtainedwith various PKC inhibitors as
well as the DAG complexing agent cremophor by several groups
[74,79,80,81] suggests the detrimental role of PKC activation in vasa
nervorum. The PKC inhibitors, WAY151003, chelerythrine and
LY333531, as well as cremophor prevented or reversed NBF and
conduction deﬁcits [74,79,80], and the PKC inhibitor bisindolylmalei-
mide-1HCl corrected acetylcholine-mediated vascular relaxation in
epineurial arterioles in the STZ-diabetic rat model [81]. The role for
neural PKC in the pathogenesis of PDN remains unclear. However,
recent ﬁndings suggest that neuronal PKC may be related to diabetes-
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the vanilloid receptor 1, known to play an important role in diabetic
neuropathic pain [82]. The novel PKC-β isoform selective inhibitor JTT-
010 was found to ameliorate nerve conduction deﬁcits, hyperalgesia
(formalin test in its ﬁrst phase) and hypoalgesia (formalin test in its
second phase, tail ﬂick test) in STZ-diabetic rats [83].
Recently, the effects of the isoform-selective PKC-beta inhibitor
ruboxistaurin mesylate on endothelium-dependent and C ﬁber-
mediated skin microvascular blood ﬂow, sensory symptoms, neuro-
logical deﬁcits, nerve ﬁber morphometry, measures of quantitative
sensory and autonomic function, nerve conduction, and quality of life
were evaluated in a randomized, double-masked, single-site, 6-month
study in human subjects with Type 1 and Type 2 diabetes [84]. In this
cohort of patients with PDN, ruboxistaurin enhanced skin micro-
vascular blood ﬂow at the distal calf, reduced sensory symptoms of
PDN, improved quality of life, and was well tolerated.
5. Role for oxidative–nitrosative stress
Enhanced oxidative stress resulting from imbalance between
production and neutralization of reactive oxygen species (ROS) is a
well recognized mechanism in the pathogenesis of PDN and other
diabetic complications i.e., endothelial dysfunction, cataract, retino-
pathy, and nephropathy. Hyperglycemia and associated increase in
aldose reductase activity, activations of non-enzymatic glycation/
glycoxidation and protein kinase C (the latter, in vasa nervorum only)
as well as other mechanisms lead to oxidative stress in diabetic
peripheral nerve (Fig. 1). Note, however, that antioxidants, including
the most potent α-lipoic acid and peroxynitrite decomposition
catalysts, do not reduce peripheral nerve glucose as well as sorbitol
pathway intermediate concentrations ([85], reviewed in [26]) in the
peripheral nerve. Recently, a signiﬁcant progress has beenmade in theFig. 1. Interactions among pathogenetic mechanisms odetection of diabetes-associated oxidative injury in tissue-sites for
PDN. New studies [85–88] have conﬁrmed previously established free
lipid peroxidation product accumulation, GSH depletion and increase
in GSSG/GSH ratio, and downregulation of superoxide dismutase
(SOD) activity in the diabetic peripheral nerve. In addition, new
markers of ROS-induced injury have been identiﬁed in peripheral
nerve, spinal cord, vasa nervorum and dorsal root ganglia (DRG) in
experimental PDN. Those include 4-hydroxynonenal protein adduct
accumulation [81], decreased catalase and total quinone reductase
activities, depletion of ascorbate and taurine and increase in
dehydroascorbate/ascorbate ratio in peripheral nerve [85,86],
increased production of superoxide in vasa nervorum [87], and
accumulation of 8-hydroxy-2′-deoxyguanosine in DRG [17] of diabetic
rats and mice. Accumulation of nitrotyrosine (a footprint of perox-
ynitrite-induced protein nitration) has been documented in periph-
eral nerve, spinal cord, vasa nervorum, and DRG in both Type 1 and
Type 2 diabetic rodent models [20,21,88–93] indicating that diabetes
creates not just oxidative, but oxidative–nitrosative stress in PNS.
Using speciﬁc markers for certain cell types of PNS, we localized
immunoreactive nitrotyrosine in endothelial and Schwann cells of
peripheral nerve, as well as neuronal and glial cells of dorsal root
ganglia, spinal cord neurons, oligodendrocytes and astrocytes (V.R.
Drel and I.G. Obrosova, unpublished) Thus, nitrosative stress affects all
major cell targets for PDN. We have also found that 1) nitrosative
stress is more severe in STZ-diabetic mice than in rats with similar
duration of diabetes (compare [91] and [92]), 2) inducible nitric oxide
synthase (iNOS) is the most important source of nitric oxide for
peroxynitrite formation in the peripheral nerve, but not DRG neurons
[94], and 3) STZ-diabetic iNOS−/− mice are, at least, partially
protected from nerve conduction deﬁcits and small sensory nerve
ﬁber neuropathy that are clearly manifest in wild-type mice with
diabetes of similar severity and duration [94]. Enhanced nitrosativef diabetic neuropathy triggered by hyperglycemia.
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[95]. Furthermore, we found highly variable accumulation of
nitrotyrosine in peripheral blood monocytes, which correlated with
fasting blood glucose, glycosylated hemoglobin, and plasma C-reactive
protein levels, in diabetic patients [96].
Numerous new studies reveal the important role of oxidative stress
in nerve functional, metabolic, neurotrophic and morphological
abnormalities characteristic for PDN. The role for ROS in diabetes-
associated nerve conduction and blood ﬂow deﬁcits has been
demonstrated in studies with the “universal” antioxidant DL-α-lipoic
acid [4,85,97,98] which is known to combine free radical and metal
chelating properties with an ability (after conversion to dehydrolipoic
acid) to regenerate levels of other antioxidants i.e., GSH, ascorbate, α-
tocopherol, catalase, glutathione peroxidase. It has also been con-
ﬁrmed with other antioxidants including the potent hydroxyl radical
scavenger dimethylthiourea, HESD [99], the SOD mimetic M40403
[87], the NAD(P)H oxidase inhibitor apocynin [100], and the xanthine
oxidase inhibitor allopurinol [101]. Furthermore, diabetes-induced
MNCV, SNCV, and nerve blood ﬂow deﬁcits, reduced reactivity of
epineurial arterioles, and small sensory nerve ﬁber degeneration
were alleviated by a peroxynitrite decomposition catalyst treatment
[89–92,102].
Several reports suggest involvement of oxidative–nitrosative stress
in the mechanisms underlying diabetic neuropathic pain and
abnormal sensory responses. Studies in the “mature” short-term rat
model of STZ-diabetes revealed thermal and mechanical hyperalgesia
(exaggerated pain state) which was corrected by lipoic acid [103], and
alleviated by the hydroxyl radical scavenger dimethylthiourea [99]. In
our studies [89–92,103], a peroxynitrite decomposition catalyst
treatment counteracted thermal and mechanical hypoalgesia in STZ-
diabetic, NOD, and ob/ob mice, as well as mechanical hyperalgesia in
rats short-term STZ-diabetes. The mechanisms underlying diabetes-
associated tactile allodynia have not been studied in detail; however, a
beneﬁcial effect of niterapone, an inhibitor of catechol-O-methyl-
transferase and antioxidant, suggests the involvement of oxidative–
nitrosative stress [104].
Two groups produced experimental evidence of an important role
for oxidative stress in diabetes-associated impairment of neurotrophic
support to the peripheral nerve by demonstrating that 1) diabetes and
prooxidant treatment caused NGF and NGF-regulated neuropeptide
i.e., substance P and neuropeptide Y, deﬁcits in the sciatic nerve that
were, at least partially, counteracted by α-lipoic acid [105]; 2) taurine
alleviated oxidative stress and prevented diabetes-induced NGF
deﬁcit in the sciatic nerve of STZ-diabetic rats [86].
Evidence for the important role of oxidative–nitrosative stress in
PDN in human subjects with diabetes mellitus is emerging. Oral
treatment with alpha-lipoic acid improved symptomatic diabetic
polyneuropathy in SYDNEY and SUDNEY 2 clinical trials [106,107].
Increased plasma nitrotyrosine content has been reported to directly
correlate with redistribution of sudomotor responses, an early sign of
sympathetic nerve dysfunction, in patients with Type 1 diabetes [95].
In a recent neuropathy study [108], plasma antioxidant capacity for
peroxynitrite (assessed by the pholasin test) correlated with the
neurological impairment score of the lower limbs (NIS-LL) in type 1
diabetic patients. Note, however, that another study from the same
group [109] did not reveal any correlations between plasma
antioxidant capacity for peroxynitrite and a number of individual
measures of nerve function in patients with both types of diabetes,
and the authors had to perform the multiple linear regression analysis
to identify the lag time for peroxynitrite disappearance from
circulation as an independent factor associated with NIS-LL. New
studies are needed to reveal if monocyte nitrosylated protein
expression (an index of intracellular nitrosative stress) can be used
as a reliable marker of the presence, severity and progression of PDN,
and if peroxynitrite decomposition catalysts display better efﬁcacy
against diabetic neuropathy than conventional antioxidants.6. Role for impaired neurotrophic support
Impaired neurotrophic support plays an important role in PDN,
and a number of neurotrophic factors including insulin, IGF-1, nerve
growth factor (NGF), ciliary neurotrophic factor, neurotrophin-3 (NT-
3), sonic hedgehog protein, and prosaposin-derived peptide have
been reported to have a beneﬁcial effect on multiple manifestations of
diabetes-induced peripheral nerve damage (recently reviewed in
[110]). Recently, insulin and IGF-1 have been shown to play an
important role in providing a remote neurotrophic support to
unmyelinated intraepidermal nerve ﬁbers [111]. Central intrathecal
delivery of IGF-1 and insulin for one month after two months of
untreated diabetes promoted intraepidermal nerve ﬁber regeneration
and increased ﬁber density. In a similar fashion, intrathecal admin-
istration of NGF and NT-3 increased myelinated innervation of the
dermal footpad of STZ-diabetic mice, which suggests that deﬁcits in
both neurotrophic factors play an important role in diabetes-
associated impairment of myelinated cutaneous innervation [112].
Neuregulins (NRGs), the growth factors that bind to Erb receptor
tyrosine kinases in Schwann cells, are known to promote cell survival,
mitogenesis, and myelination in undifferentiated SCs, but also to
induce demyelination of myelinated SC. A recent elegant study in co-
cultures of SC and DRG neurons revealed the role of hyperglycemia-
induced increase in Erb B2 activity and concomitant downregulation
of the protein caveolin-1 in NGG-induced SC demyelination [113]. The
study provides rationale for development of principally novel
therapeutic approaches, to counteract demyelination, a major struc-
tural disorder associated with human PDN.
7. Role for poly(ADP-ribose)polymerase activation
The enzyme poly(ADP-ribose) polymerase (PARP) is localized in
the nucleus and mitochondria, and cleaves nicotinamide adenine
dinucleotide (NAD+) with formation of nicotinamide and ADP-ribose
residues which are attached to nuclear proteins and to PARP itself,
with formation of poly(ADP-ribosyl)ated protein polymers [114]. Until
recently, a conservative view on PARP activation as a phenomenon
arising from free radical- and peroxynitrite-induced DNA single-
strand breakage hampered studies of the role for other mechanisms in
excessive poly(ADP-ribosyl)ation in pathological conditions asso-
ciated with oxidative stress including diabetic complications. How-
ever, several new studies [115–117] including those from our
laboratory [117] revealed that 1) in some tissues, e.g., peripheral
nerve, PARP activationmay precede rather than result from oxidative–
nitrosative stress, and 2) PARP activation does not necessarily require
DNA single-strand breakage, and may occur due to phosphorylation
by phosphorylated ERK. PARP activation leads to 1) NAD+ depletion
and energy failure [7,114,118]; 2) changes of transcriptional regulation
and gene expression [40,42,114]; 3) poly(ADP-ribosyl)ation and
inhibition of the glycolytic enzyme glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) resulting in diversion of the glycolytic ﬂux
towards several pathways implicated in diabetes complications [119].
Recent studies of our group [7,118,120,121] revealed that PARP
activation is an early and fundamental mechanism of PDN. It is clearly
manifest in peripheral nerve, vasa nervorum, and DRG neurons of STZ-
diabetic rats [7,92,118,120,121] as well as peripheral nerves, spinal
cord, and DRG of STZ-diabetic [91,121], ob/ob [20,90], and HFD-fed
[21] mice. Using endothelial and Schwann cell markers and double
immunostaining [7], we localized PARP activation in endothelial and
Schwann cells of diabetic rat nerve. Our group was ﬁrst to develop the
Western blot analysis of poly(ADP-ribosyl)ated proteins in rat sciatic
nerve [122]; using this approach, we found poly(ADP-ribosyl)ated
protein abundance increased by 74% in rats with 4-wk duration of STZ-
diabetes compared with non-diabetic controls. Furthermore, we
found accumulation of poly(ADP-ribosyl)ated proteins to develop
very early, i.e. within ~12–24 h of exposure of cultured human
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abundance was not affected by high glucose or PARP inhibitor
treatment in either cell type consistent with the current knowledge
on PARP-1 as abundantly expressed enzyme with very minor, if any,
transcriptional regulation [114].
Using several structurally unrelated PARP inhibitors and PARP-
deﬁcient (PARP−/−) mice, we revealed the important role for PARP
activation in MNCV and SNCV deﬁcits, neurovascular dysfunction,
sensory neuropathy, peripheral nerve energy failure, intraepidermal
nerve ﬁber loss, and axonal atrophy associated with peripheral diabetic
neuropathy [7,118,120,121]. PARP−/− mice were protected from both
diabetic and galactose-induced MNCV and SNCV deﬁcits and nerve
energy failure that were clearly manifest in the wild-type (PARP+/+)
diabetic or galactose-fed mice [7]. Furthermore, whereas diabetic wild-
type mice developed clearly manifest thermal and mechanical
hypoalgesia, tactile allodynia, and intraepidermal nerve ﬁber loss,
diabetic PARP−/− mice did not display any manifestations of small
sensory nerve ﬁber neuropathy, andmaintained normal intraepidermal
nerve ﬁber density [121]. The data in PARP−/− mice are consistent
with the ﬁndings obtained in pharmacological studies. Two structurally
unrelated PARP inhibitors, 3-aminobenzamide and 1,5-isoquinoline-
diol, reversed established nerve blood ﬂow and conduction deﬁcits and
energy deﬁciency in STZ-diabetic rats [7]. Alleviation of diabetes-
associated neurovascular dysfunction and nerve conduction deﬁcits
was also achieved with a relatively weak PARP inhibitor, nicotinamide
[123]. Another PARP inhibitor, PJ34, essentially corrected nerve
conduction deﬁcits and energy deﬁciency despite relatively modest
(17%) reversal of nerve blood ﬂow deﬁcit [118]. The latter is consistent
with normalization of free NAD+/NADH ratio, an index of tricarboxylic
cycle activity and glucose utilization, in the peripheral nerve
mitochondrial matrix of PJ34-treated diabetic rats [118]. In the same
study, PJ34 treatment counteracted decrease in free cytosolic NAD+/
NADH ratio, accumulation of lactate and glutamate, and depletion of α-
glutarate in diabetic peripheral nerve. Nerve glucose and sorbitol
pathway intermediate concentrations were similarly elevated in PJ34-
treated and untreated rats which is consistent with the downstream
localization of PARP activation, consequent to increased AR activity, in
the pathogenesis of diabetic complications [26]. In our most recent
study [121], the orally active PARP inhibitor 10-(4-methylpiperazin-1-
ylmethyl)-2H-7-oxa-1,2-diaza-benzo[de]anthracen-3-one (GPI-15427;
formulated as a mesilate salt, 30 mg kg(−1) day(−1) in the drinking
water for 10 weeks after the ﬁrst 2 weeks without treatment) at least
partially prevented PARP activation in peripheral nerve and DRG
neurons, as well as thermal hypoalgesia, mechanical hyperalgesia,
tactile allodynia, exaggerated response to formalin, and, most impor-
tantly, intraepidermal nerve ﬁber degeneration in streptozotocin-
diabetic rats. We have also reported neuroprotective effects of PARP
inhibitor-containing combination therapies [122]. In particular, com-
bined treatments with low-dose PARP inhibitor and one of two
vasodilators i.e., the ACE-inhibitor lisinopril and β-adrenoceptor
agonist salbutamol, resulted in reversal of neurovascular dysfunction,
SNCV deﬁcit (MNCV deﬁcit was reversed by salbutamol-, but not
lisinopril-containing drug combination) as well as thermal and
mechanical hyperalgesia in rats with short-term STZ-diabetes [122].
Theoretically, PARP activation can contribute to diabetic neuropathic
pain and abnormal sensory responses via several mechanisms
including but not limited to 1) upregulation of tumor necrosis factor-
alpha (TNF-α) and other inﬂammatory genes; 2) activation of p38MAP
kinase in the spinal cord and Schwann cells; and 3) Ca++-regulated
excitotoxic insults, all of which have been implicated in the pathogen-
esis of painful neuropathy [124,125,126].
8. Role for mitogen-activated protein kinase (MAPK) activation
Numerous ﬁndings indicate that ROS and reactive nitrogen species
cause MAPK activation [13,15,127], and increasing evidence supportsthe importance of MAPKs in the pathogenesis of PDN. ERK, p38MAPKs
and JNK are activated in DRG neurons of STZ-diabetic rats [13,15]. Sural
nerve JNK activation and increases in total levels of p38 and JNK have
been observed in patients with both Type 1 and Type 2 diabetes
[13,15]. MAPKs are implicated in aberrant neuroﬁlament phosphor-
ylation, a phenomenon involved in the etiology of the diabetic sensory
polyneuropathy [128]. Fernyhough et al. [128] have reported a 2–3-
fold elevation of neuroﬁlament phosphorylation in lumbar DRG of
STZ-diabetic and spontaneously diabetic BB rats, as well as 2.5-fold
elevation in neuroﬁlament M phosphorylation in sural nerve of BB
rats. Diabetes-induced 3–4-fold increase in phosphorylation of a
54-kDa isoform of JNK in DRG and sural nerve correlated with
elevated c-Jun and neuroﬁlament phosphorylation. p38 activation in
DRG neurons of STZ-diabetic rats is prevented by the ARIs sorbinil and
ﬁdarestat which suggests the important role of AR in diabetes-related
alterations in MAPK signaling [13, 129]. The p38 MAPK inhibitor
SB239063 corrected MNCV and SNCV deﬁcit in STZ-diabetic rats thus
implicating p38 MAPK in motor and sensory nerve dysfunction [129].
In the same animal model, the p38-α MAPK inhibitor SD-282
counteracted mechanical allodynia, C-, but not Adelta-ﬁber-mediated
thermal hyperalgesia, and attenuated ﬂinching behavior during the
quiescent period and the second phase of the formalin response [130].
Spinal p38 MAPK has also been implicated in the neuropathic pain
induced by inﬂammation [131].
9. Role for NF-κB activation
Both PARP-1 and MAPKs are involved in transcriptional regula-
tion of gene expression, via the transcription factors NF-κB, activator
protein-1, p53, and others [40,41,114]. Activated NF-κB has been
identiﬁed in perineurium, epineurial vessels and endoneurium in
sural nerve biopsies of subjects with impaired glucose tolerance [69]
and overt diabetes [58]. NF-κB activation was also found in isolated
Schwann cells cultured in high glucose medium compared with
those in low glucose [132], and such activation was prevented by the
ARI ﬁdarestat. Activation of NF-κB and other transcription factors by
high glucose and oxidative stress [133] leads to upregulation of
inducible nitric oxide synthase, cyclooxygenase-2, endothelin-1, cell
adhesion molecules and inﬂammatory genes [40,42]. Growing
evidence indicates that the afore-mentioned transcription factors
and their target genes are involved in the pathogenesis of diabetic
complications, and, in particular, PDN [8]. Thus, it is not surprising
that inhibition of NF-κB by pyrrolidine dithiocarbamate and the
serine protease inhibitor N-alpha-tosyl-L-lysine chloro-methylketone
(TLCK) i.e. IκB protease activity-blocking agent, corrected nerve
conduction and blood ﬂow deﬁcits in STZ-diabetic rats [8]. In the
same animal model, TLCK also partially reversed gastric autonomic
neuropathy [8].
10. Roles for cyclooxygenase-2 (COX-2) and 12/15-Lipoxygenase
(12/15-LO) activation
Evidence for the important role of arachidonic acid metabolic
pathways i.e. COX-1 and COX-2, cytochrome p450 epoxygenase and
lipoxygenases in diabetes complications is emerging. The lipid
products of these pathways include thromboxane, prostaglandins,
leukotrienes, lipoxins, epoxyeicosatrienoic (EET) acid, 12-hydroper-
oxy-eicosatetraenoic acid (12-HPETE), 12-HETE, 15-HETE and a whole
variety of their derivatives. COX-1 protein expression was reported
unchanged in the diabetic peripheral nerve [9] and reduced in the
spinal cord [134] whereas COX-2 protein expression was increased in
both tissues [9, 38]. COX-2 activity was also increased in the diabetic
spinal cord, and was localized to spinal cord oligodendrocytes [38].
Selective COX-2 inhibitors were reported to prevent motor nerve
conduction and endoneurial nutritive blood ﬂow deﬁcits, peripheral
nerve oxidative stress and inﬂammation [9,135], as well as spinal
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test) in the diabetic rats [38]. Diabetic COX-2 deﬁcient mice were
protected from MNCV and SNCV slowing, intraepidermal nerve ﬁber
loss, and oxidative damage that was clearly manifest in the diabetic
wild-type mice [135]. One of the most interesting members of the
lipoxygenase family is 12/15-LO, a nonheme iron-containing dioxy-
genase that forms 12-HPETE and 12- and 15-HETEs and oxidizes
esteriﬁed arachidonic acid in lipoproteins (cholesteryl esters) and
phospholipids [136,137]. 12/15-LO is abundantly expressed in
endothelial cells (e.a., aortic and retinal endothelial cells), smooth
muscle cells, monocyte/macrophages, as well as renal mesangial cells,
tubular epithelial cells, and podocytes, and the enzyme expression is
increased under diabetic and hyperglycemic conditions [136,137].
Recent in vivo and cell culture studies revealed that high glucose-
induced 12/15-LO activation affects multiple metabolic and signal
transduction pathways, transcriptional regulation and gene expres-
sion [136,137]. The major consequences include increased free radical
production and lipid peroxidation, MAPK and NF-κB activation,
inﬂammatory response, excessive growth, as well as adhesive and
chemoattractant effects. Recent ﬁndings from our group suggest an
important role for 12/15-LO activation in peripheral DN [138]. In
particular, we found that 1) 12/15-LO is abundantly expressed in
mouse peripheral nerve and its expression increases in diabetic
conditions; 2) 12/15-LO−/− mice with both Type 1 (streptozotocin-
induced) and Type 2 (high fat diet-induced) diabetes develop less
severe peripheral DN than wild-type mice; 3) some manifestations of
peripheral DN in STZ-diabetic mice are reversed by a short-term 12/
15-LO inhibitor treatment; 4) 12/15-LO is abundantly expressed in
human Schwann cells (HSC), one of the major cell targets in human
DN, and its overexpression is clearly manifest after a short-term (24 h)
exposure to high glucose; and 5) 12/15-LO overexpression in high
glucose-exposed HSC contributes to activation (phosphorylation) of
all three subtypes of MAPKs including p38 MAPK, ERK 1/2 and JNK-1,
recently implicated in the pathogenesis of both experimental and
human DN [21,138]. These results provide the rationale for detailed
studies of the role for 12/15-LO pathway in diabetic neuropathic
changes.
11. Roles for altered Ca++ homeostasis and signaling
Growing evidence suggests that diabetic sensory neuropathy is
associated with abnormal Ca++ homeostasis and signaling in DRG
neurons [139,140]. Enhanced Ca++ inﬂux via multiple high-threshold
calcium currents is present in sensory neurons of several rat models of
diabetes mellitus, including the spontaneously diabetic BioBred/
Worchester (BB/W) rats and STZ-diabetic rats [139]. Sensory neurons
of STZ-diabetic rats have increased mRNA expression of voltage-gated
calcium channels [140]. Enhanced calcium entry in diabetes is also
linked to the impairment of G-protein-coupled modulation of calcium
channel function [139]. Increased AR activity and taurine deﬁciency
contribute to diabetes-related enhancement of voltage-dependent
calcium currents in DRG neurons [141,142]. These two mechanisms
probably converge at the level of oxidative stress and resulting PARP
activation known to promote [Ca2+]i accumulation and impair
calcium signaling.
Evidence for important role of [Ca2+]i in neuropathic pain of
different origin, and, in particular, diabetic neuropathic pain is
emerging. Luo et al. [143] found that injury type-speciﬁc calcium
channel alpha2delta-1 subunit upregulation in rat neuropathic pain
models (mechanical nerve injuries, diabetic neuropathy, chemical
neuropathy) correlated with antiallodynic effect of the anticonvulsant
gabapentin. Furthermore, a recent 6-week, randomized, double-blind,
multicenter clinical trial in 246 patients with painful diabetic
neuropathy revealed that pregabalin, a new drug that interacts with
the alpha2-delta protein subunit of the voltage-gated calcium
channel, is a efﬁcacious and safe treatment for diabetic neuropathicpain [144]. Similar ﬁndings have been obtained in another 12-week,
randomized, double-blind, multicenter, placebo-controlled trial of
pregabalin that revealed a signiﬁcant pain relief in patients with
chronic postherpetic neuralgia or painful diabetic neuropathy [145].
12. Role for Na+/H+-exchanger-1 activation
Recent studies from our group suggest an important role for
Na+/H+-exchanger-1 (NHE-1) in PDN [146]. The NHE-1 speciﬁc
inhibitor cariporide, at least, partially prevented MNCV and SNCV
deﬁcits, thermal hypoalgesia, mechanical hyperalgesia, and tactile
allodynia in STZ-diabetic rats. STZ-diabetic NHE-1+/−mice developed
less severe early PDN than thewild-typemice. Increased NHE-1 protein
expression and activity were found early (~24 h) after exposure of
human endothelial and Schwann cells to high glucose thus suggesting
that this mechanism can be of importance in human PDN.
13. Conclusion
Multiple mechanisms are involved in the pathogenesis of PDN.
New ﬁndings support the role for previously discovered mechanisms
such as increased AR activity, non-enzymatic glycation/glycoxidation,
PKC activation, oxidative stress, and impaired neurotrophic support in
functional and morphological abnormalities in the diabetic nerve.
Evidence for the important role for nitrosative stress, MAPK activation,
PARP activation, COX-2 activation and Ca++ signaling is emerging.
Several newly discovered mechanisms include activations of NF-κB,
the 12/15-lipoxygenase pathway and Na+/H+ exchanger-1. Most of
the pathogenetic mechanisms converge at the level of oxidative–
nitrosative stress which is likely to be a central mechanism in PDN
(Fig. 1). Studies of the roles for individual mechanisms leading to
oxidative–nitrosative stress and PDN, and their interactions with each
other are in progress.
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